Recon: NIH may own IP for Moderna COVID-19 vaccine; UniQure sells gene therapy rights to CSL for $450M

• Trump’s Drug Push Still Keeps Door Open for Banned Indian Firm (Bloomberg)
• Bolton casts light on Trump’s deference to China on coronavirus (Politico)
• Trump administration ending support for drive-thru testing sites (Politico)
• Breakthrough Drug for Covid-19 May Be Risky for Mild Cases (NYTimes)
• The NIH claims joint ownership of Moderna's coronavirus vaccine (Axios)
• Moderna adds Catalent as vaccine manufacturing partner (BioPharmaDive)
• Democrat raises questions about Trump administration's deliveries of ventilators abroad (NBC)
• US group raises pricing recommendation for Gilead's remdesivir in COVID-19 (Reuters)
• Hospitals see shortages of a cheap steroid that one study says helps Covid-19 patients (STAT)
• Merck treads on Sanofi, Regeneron's turf with Keytruda's latest skin cancer OK (Fierce) (Endpoints)

• Sosei, AbbVie sign drug discovery deal worth up to $1 bln (Reuters) (Endpoints)
• Vaccine alliance finds manufacturing capacity for 4 billion doses of coronavirus vaccines (Reuters)
• In a surprise, UniQure sells its hemophilia gene therapy for $450M (BioPharmaDive) (Endpoints) (PMLive)
• Australian drugmakers hit by critical shortages at height of pandemic, inquiry hears (The Guardian)
• Germany flexes its muscles on foreign investment (Financial Times)
• World's second-worst Ebola outbreak formally ends (The Hill) (WHO)
• Coronavirus: Vaccine volunteers begin to get immunized (BBC)
• A pill to fight alcoholism causes an uproar in France over a regulator’s view of a clinical trial (STAT)
• NICE knocks back Novartis’ oral MS drug Mayzent in draft guidance (PMLive)
• NICE green light for Roche's Rozlytrek (PharmaTimes)
• Sustained decline in sleeping sickness cases puts elimination within reach (WHO)

• Decades-Old Soviet Studies Hint at Coronavirus Strategy (NYTimes)
• Price for Gilead's COVID-19 drug should shrink if cheap steroid widely used, ICER says (BioPharmaDive)
• Trump promised to pay for Covid care. But patients with long-term symptoms see huge bills. (Politico)
• Where The Women Aren't: On Coronavirus Task Forces (NPR)
• CDC Is Still Inaccurately Counting Coronavirus Tests, a Watchdog Agency Finds (NYTimes)
• Study Raises Concerns for Pregnant Women With the Coronavirus (NYTimes)
• How will the world's poorest people get a coronavirus vaccine? (The Guardian)
• Arizona ‘Overwhelmed’ With Demand for Tests as U.S. System Shows Strain (NYTimes)
• How Orphan Drug Policy Could Impede Access To COVID-19 Treatments (Health Affairs)
• LabCorp launches COVID-19 test to track neutralizing antibodies (Fierce)
• CVS launches return-to-work service, including in-house COVID-19 testing option (MedtechDive)
• Partnering with the European Union and Global Regulators on COVID-19 (FDA)
• Coronavirus (COVID-19) Update: Daily Roundup June 24, 2020 (FDA)
• Coronavirus (COVID-19) Update: Joint Statement from USDA and FDA on Food Export Restrictions Pertaining to COVID-19 (FDA)

• Why Aren’t FDA Drug Facility Inspections Resuming? (FDA Law Blog)
• Virtual clinical trials now being used to fast-track drug development during coronavirus crisis (CNBC)
• Approval of Denosumab biosimilar and launch of teriparatide biosimilar in China and South Korea (Big Molecule Watch)
• Yale spinout re-engineers an immunotherapy GSK, others once abandoned (Endpoints)
• AstraZeneca touts triplet inhaler Breztri's COPD win ahead of key FDA decision (Fierce)
• New research highlights how biases play a role in FDA drug approvals (Pharmafile)
• Decentralized Trials Guidance May Reflect US FDA’s Lessons Learned During COVID-19 (Pink Sheet)
• Alzheimer's Researchers Go Back To Basics To Find The Best Way Forward (NPR)
• Over a decade ago, a disastrous trial killed research on a potential immunotherapy. Can a Regeneron bispecific revive it? (Endpoints)
• CRISPR Therapeutics blueprints cell therapy manufacturing site; Regeneron fights back against kickback claims (Endpoints)
• Relay and iTeos join IPO deluge while Akouos and Fusion decide they can earn more (Endpoints)
• Takeda joins microbiome-focused biotech partner's $52.6M raise as it pursues more in-house cancer work (Endpoints)
• Acceleron promised they had great data on sotatercept in late January. But was it good enough to justify a doubling of the stock price? (Endpoints)
• Indian pharma consignments from China held by customs, importers worried (PharmaBiz)

• FDA approves Medtronic’s latest DBS (MassDevice)
• PBM RemedyOne will offer Pear Therapeutics reSET, reSET-O (MobiHealthNews)
• Philips wins FDA approval for new automated external defibrillators (MassDevice)
• FDA clears Preceptis Medical’s in-office ear tube placement for kids (MassDevice)

• Mylan, seeking to market Victoza generic, convinces panel to start up patent review (Fierce)
• J&J Surgical Rip-Offs Lead To Seizure, FDA Criminal Probe (Law360)
• Full Fed. Circ. Skips Biogen Fight Over MS Drug Patent (Law360)
• An Inside Look At DOJ Fight Against COVID-19 Price-Gouging (Law360)
• Prevagen Maker Inks Deal To Settle Half-Dozen False Ad Suits (Law360)
• Roundup Maker to Pay $10 Billion to Settle Cancer Suits (NYTimes)
• He Removed Labels That Said “Medical Use Prohibited,” Then Tried to Sell Thousands of Masks to Officials Who Distribute to Hospitals (ProPublica)
• Senate Bills Would Require More COVID-19 PPE, US Manufacturing Capacity, Use Of Analytical Imaging (MedtechInsight)
• Country of origin and medicine quality (TGA)